Lung transplantation for pulmonary fibrosis secondary to severe COVID-19
ABSTRACT Lung transplantation can potentially be a life-saving treatment for patients with non-resolving COVID-19 acute respiratory distress syndrome. Concerns limiting transplant include recurrence of SARS-CoV-2 infection in the allograft, technical challenges imposed by viral-mediated injury to the native lung, and potential risk for allograft infection by pathogens associated with ventilator-induced pneumonia in the native lung. Additionally, the native lung might recover, resulting in long-term outcomes preferable to transplant. Here, we report the results of the first two successful lung transplantation procedures in patients with non-resolving COVID-19 associated acute respiratory distress syndrome in the United States. We performed smFISH to detect both positive and negative strands of SARS-CoV-2 RNA in the explanted lung tissue, extracellular matrix imaging using SHIELD tissue clearance, and single cell RNA-Seq on explant and warm post-mortem lung biopsies from patients who died from severe COVID-19 pneumonia. Lungs from patients with prolonged COVID-19 were free of virus but pathology showed extensive evidence of injury and fibrosis which resembled end-stage pulmonary fibrosis. Single cell RNA-Seq of the explanted native lungs from transplant and paired warm post-mortem autopsies showed similarities between late SARS-CoV-2 acute respiratory distress syndrome and irreversible end-stage pulmonary fibrosis requiring lung transplantation. There was no recurrence of SARS-CoV-2 or pathogens associated with pre-transplant ventilator associated pneumonias following transplantation in either patient. Our findings suggest that some patients with severe COVID-19 develop fibrotic lung disease for which lung transplantation is the only option for survival.Single sentence summary Some patients with severe COVID-19 develop end-stage pulmonary fibrosis for which lung transplantation may be the only treatment..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 10. Apr. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bharat, Ankit [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.10.26.20218636 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019217803 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019217803 | ||
| 003 | DE-627 | ||
| 005 | 20230429084928.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201028s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.10.26.20218636 |2 doi | |
| 035 | |a (DE-627)XBI019217803 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.10.26.20218636 | ||
| 035 | |a (biorXiv)10.1101/2020.10.26.20218636 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Bharat, Ankit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lung transplantation for pulmonary fibrosis secondary to severe COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Lung transplantation can potentially be a life-saving treatment for patients with non-resolving COVID-19 acute respiratory distress syndrome. Concerns limiting transplant include recurrence of SARS-CoV-2 infection in the allograft, technical challenges imposed by viral-mediated injury to the native lung, and potential risk for allograft infection by pathogens associated with ventilator-induced pneumonia in the native lung. Additionally, the native lung might recover, resulting in long-term outcomes preferable to transplant. Here, we report the results of the first two successful lung transplantation procedures in patients with non-resolving COVID-19 associated acute respiratory distress syndrome in the United States. We performed smFISH to detect both positive and negative strands of SARS-CoV-2 RNA in the explanted lung tissue, extracellular matrix imaging using SHIELD tissue clearance, and single cell RNA-Seq on explant and warm post-mortem lung biopsies from patients who died from severe COVID-19 pneumonia. Lungs from patients with prolonged COVID-19 were free of virus but pathology showed extensive evidence of injury and fibrosis which resembled end-stage pulmonary fibrosis. Single cell RNA-Seq of the explanted native lungs from transplant and paired warm post-mortem autopsies showed similarities between late SARS-CoV-2 acute respiratory distress syndrome and irreversible end-stage pulmonary fibrosis requiring lung transplantation. There was no recurrence of SARS-CoV-2 or pathogens associated with pre-transplant ventilator associated pneumonias following transplantation in either patient. Our findings suggest that some patients with severe COVID-19 develop fibrotic lung disease for which lung transplantation is the only option for survival.Single sentence summary Some patients with severe COVID-19 develop end-stage pulmonary fibrosis for which lung transplantation may be the only treatment. | ||
| 700 | 1 | |a Querrey, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Markov, Nikolay S. |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Kurihara, Chitaru |e verfasserin |4 aut | |
| 700 | 1 | |a Garza-Castillon, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Manerikar, Adwaiy |e verfasserin |4 aut | |
| 700 | 1 | |a Shilatifard, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Tomic, Rade |e verfasserin |4 aut | |
| 700 | 1 | |a Politanska, Yuliya |e verfasserin |4 aut | |
| 700 | 1 | |a Abdala-Valencia, Hiam |e verfasserin |4 aut | |
| 700 | 1 | |a Yeldandi, Anjana V. |e verfasserin |4 aut | |
| 700 | 1 | |a Lomasney, Jon W. |e verfasserin |4 aut | |
| 700 | 1 | |a Misharin, Alexander V. |e verfasserin |4 aut | |
| 700 | 1 | |a Budinger, G.R. Scott |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 10. Apr. |
| 773 | 1 | 8 | |g year:2021 |g day:10 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1126/scitranslmed.abe4282 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.10.26.20218636 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 10 |c 04 | ||
| 953 | |2 045F |a 570 | ||